Vircell S.L.

Vircell is a biotechnology company specializing in the development and production of ready-to-use reagents for the di... read more

Vircell Presents Latest Offerings and Products in Diagnostic Testing

By LabMedica International staff writers
Posted on 12 Nov 2024

Image: Vircell is highlighting the VirClia Lotus instrument at MEDICA 2024 (Photo courtesy of Vircell)

Vircell (Granada, Spain) is attending this year’s MEDICA where the company is highlighting its latest offerings as well as upcoming products.

At MEDICA 2024, Vircell is highlighting the VirClia Lotus instrument based on its monotest technology to process infectious disease immunoassays for human diagnostic applications. VirClia Lotus accepts any combination of samples and reagents, regardless of the instrument status. Even while running, it remains accessible for reagent and sample addition. VirClia Lotus’ built-in scanner allows for full traceability of both samples and strips, avoiding clerical errors. This true monotest solution allows the laboratory to run low-volume infectious serology tests daily, alongside the laboratory routine. VirClia Lotus unifies all the parameters typically performed with ELISA, IFA or rapid tests in just one chemiluminescent immunoassay (CLIA) system.

Among its wide range of rapid tests, Vircell is showcasing its new ASPERGILLUS GALACTOMANNAN Ag VIRCLIA MONOTEST for the detection of invasive aspergillosis as an aid for the early diagnosis of this life-threatening disease. This sandwich CLIA is intended for the detection of Aspergillus galactomannan antigen in serum, plasma and human bronchoalveolar lavage (BAL) samples. Vircell is also showcasing the HELICOBACTER PYLORI Ag VIRCLIA MONOTEST, an innovative, fully automated single-test format for detecting H. pylori antigen in stool samples. This sandwich CLIA test simplifies sample preparation by eliminating the need for centrifugation, using a tube with a built-in filter instead.

Additionally, Vircell is highlighting the INVASIVE CANDIDIASIS (CAGTA) VIRCLIA IgG MONOTEST for the early detection of invasive candidiasis (IC) that discriminates infection from colonization. This indirect CLIA is intended to detect IgG antibodies against antigens located on the cell wall surface of the micelium of Candida albicans (CAGTA, Candida albicans germ tube antibody) in human serum/plasma. Visitors to the Vircell booth can also learn about the company’s CLIAs to detect antibodies against hepatitis E virus in human serum or plasma samples. These assays offer a complete solution as an aid in the diagnosis of hepatitis E: HEV IgM, HEV IgG, and HEV IgG avidity.

Related Links:
Vircell